Mixed Signals for Healthcare's Role as an AI Hedge

While strong portfolio growth and valuation updates for some pharmaceutical giants support their use as a defensive play, clinical trial setbacks and operational risks in others introduce volatility that complicates the sector's role as a stable hedge against technology sell-offs.

What changed

Several key developments have emerged across the healthcare landscape. Amgen (AMGN) saw its modeled fair value rise from $352.23 to $371.93 following a Q2 beat and subsequent analyst target hikes. Similarly, AbbVie reported that each of its core portfolios delivered growth exceeding 20%, with SKYRIZI achieving significant market leadership. In contrast, Novo Nordisk is navigating a complex period; while the company won a Dutch injunction regarding its Semaglutide spray and continues to see GLP-1 volume growth, it has also faced a "rough patch" with shares falling 15% this year following missed guidance targets and the failure of the Ziltivekimab heart trial. Additionally, Merck (MRK) lowered its 2026 profit forecast due to costs associated with the Terns acquisition, while Amgen is currently managing a patient data breach. On the clinical front, MSD and Gilead opted to scrap their Phase III Trodelvy-Keytruda study following lackluster interim data.

Why it matters

The core of the healthcare hedge thesis relies on the sector's ability to provide stability when high-growth tech stocks face valuation compression. The positive updates for Amgen and AbbVie reinforce this; specifically, the upward revision of Amgen’s fair value and AbbVie’s consistent double-digit growth suggest that these entities possess the fundamental strength to act as a reliable anchor. However, the setbacks for Novo Nordisk and the scrapped MSD/Gilead study introduce significant nuance. If major players in the GLP-1 space or oncology sectors face clinical failures or manufacturing hurdles, their ability to serve as a "safe haven" is diminished because they become subject to the same volatility seen in other high-growth sectors. Furthermore, non-clinical risks—such as Amgen’s data breach and Merck’s acquisition-related profit cuts—introduce operational variables that can cause sudden price movements regardless of underlying drug efficacy, potentially weakening the thesis that healthcare is a purely defensive rotation.

Opposing sources and risks

The thesis faces pressure from several factors: the cancellation of the Trodelvy-Keytruda study by MSD and Gilead suggests some pipeline components are not meeting expectations; Amgen’s data breach poses an operational risk to its valuation; and Merck’s lowered profit forecast due to acquisition costs introduces a drag on near-term earnings. Additionally, Novo Nordisk's recent trial failures and subsequent share price volatility suggest that the GLP-1 segment may contain more idiosyncratic risks than previously assumed in a defensive rotation.\n

What to watch

  • Follow-up analyst revisions for Merck following the integration of Terns.
  • Progress on Amgen’s resolution of its data breach and subsequent impact on valuation.
  • Further trial results from other GLP-1 candidates to determine if Novo Nordisk's struggles are isolated or systemic.
  • Upcoming FDA decisions regarding Scholar Rock’s Apitegromab BLA.

Related Arbora context

  • concept-glp1-obesity-drug-coverage
  • concept-healthcare-managed-care-aging-demographics
  • concept-pfizer-largecap-pharma-value-recovery
  • concept-abbvie-largecap-pharma-ma-pipeline-build
  • concept-pharma-china-supply-chain-decoupling-pressure

Sources

This is research notes, not financial advice.